ENDP : Summary for Endo International plc - Yahoo Finance

U.S. Markets closed

Endo International plc (ENDP)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
11.46+0.72 (+6.70%)
At close: 4:00PM EDT

11.44 -0.02 (-0.17%)
After hours: 5:50PM EDT

People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close10.74
Bid11.25 x 200
Ask11.47 x 100
Day's Range10.71 - 11.55
52 Week Range9.70 - 35.34
Avg. Volume9,262,734
Market Cap2.56B
PE Ratio (TTM)-0.76
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Will Endo's Troubles Continue to Dent Performance in 2017?

    Will Endo's Troubles Continue to Dent Performance in 2017?

    2017 will continue to challenging for Endo Pharmaceuticals (ENDP) as the generics base business and the legacy branded pain franchise are expected to decline further.

  • Investopediayesterday

    Will Endo's Troubles Continue to Dent Performance in 2017?

    We issued an updated research report on Endo International plc ENDP on Mar 27, 2017. Endo, a global specialty pharmaceutical company focused on branded and generic pharmaceuticals, came into existence ...

  • Barrons.com2 days ago

    Shire: Can It Pay Down Debt?

    Gimme Credit is taking drug maker Shire (SHPG) to task today, but not for the load of debt it piled onto its once pristine balance sheet when it acquired U.S. drug make Baxalta last year. Rather, analyst Carol Levenson complains that while company has made progress paying down its management still doesn’t know how to talk to bond investors. According to Levenson, Shire, which unveiled terms of its $32 billion purchase of the Baxter (BAX) spinoff in January 2016, has never released detailed plans for deleveraging its balance sheet.